{"nctId":"NCT00674154","briefTitle":"Effect of Vitamin D Treatment in Primary Hyperparathyroidism","startDateStruct":{"date":"2008-05"},"conditions":["Vitamin D Deficiency","Primary Hyperparathyroidism","Hypercalcemia"],"count":46,"armGroups":[{"label":"Vitamin D group","type":"EXPERIMENTAL","interventionNames":["Drug: Cholecalciferol"]},{"label":"Placebo group","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Cholecalciferol"]}],"interventions":[{"name":"Cholecalciferol","otherNames":["vitamin D"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* P-Ca-ion \\> 1,30 mmol/l\n* P-PTH \\> 5 pmol/l\n* P-OH25-vitamin D \\< 80 nmol/l\n\nExclusion Criteria:\n\n* P-creatinin \\> 120 mumol/l\n* usage of Etalpha, Mimpara\n* Cancer\n* Sarcoidosis\n* malabsorption\n* pancreatitis\n* alcohol abuse\n* pregnancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Decrease in Preoperative P-PTH","description":"Decrease in plasma PTH after 25 weeks of preoperative vitamin D treatment compared with the plasebo Group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"0.7"},{"groupId":"OG001","value":"0.2","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Improved Muscular Function","description":null,"classes":[]},{"type":"SECONDARY","title":"Reduced Postoperative Hypocalcemia","description":null,"classes":[]},{"type":"SECONDARY","title":"Increase in Quality of Life","description":null,"classes":[]},{"type":"SECONDARY","title":"Increased Bone Mineral Density","description":null,"classes":[]},{"type":"SECONDARY","title":"Increase in Trabecular and Cortical vBMD Measured by QCT and pQCT of Hip, Spine and Forearm","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":20},"commonTop":["Eye infection","Lower leg cramp","Pneumonia","Abdominal pain","Steatosis hepatis"]}}}